Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer.[4][5][6] It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC.[7][8][9] It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.[10] Some clinical trial results were announced in 2017.[11] On 26 November 2018, Larotrectinib was approved by the FDA.[12]
Larotrectinib was the first drug to be specifically developed and approved to treat any cancer containing certain mutations, as opposed to cancers of specific tissues (i.e., the approval is "tissue agnostic"). Several earlier drugs, including pembrolizumab, were eventually approved by the FDA for treatment of specific mutations independent of the type of cancer, but those drugs had been initially developed for specific cancer types.[13] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[14]
Phase II clinical trials evaluating the drug for efficacy and safety in treating several types of solid tumors are ongoing.[15]
Larotrectinib was approved for medical use in the European Union in September 2019.[16][17] It was approved for medical use in Australia in August 2020.[4]
Recent publications have also highlighted advancements in optimizing the manufacturing process of Larotrectinib using continuous flow chemistry, improving its scalability and purity.[18]
^"Larotrectinib"(PDF). Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association (AMA). 26 October 2016.
^Berger S, Martens UM, Bochum S (2018). "Larotrectinib (LOXO-101)". Small Molecules in Oncology. Recent Results in Cancer Research Fortschritte der Krebsforschung. Progres dans les Recherches Sur le Cancer. Vol. 211. pp. 141–151. doi:10.1007/978-3-319-91442-8_10. ISBN978-3-319-91441-1. PMID30069765.
^Clinical trial number NCT02576431 for "A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors" at ClinicalTrials.gov
This browser is not supported by Wikiwand :( Wikiwand requires a browser with modern capabilities in order to provide you with the best reading experience. Please download and use one of the following browsers:
Your input will affect cover photo selection, along with input from other users.
X
Get ready for Wikiwand 2.0 🎉! the new version arrives on September 1st! Don't want to wait?
Oh no, there's been an error
Please help us solve this error by emailing us at support@wikiwand.com
Let us know what you've done that caused this error, what browser you're using, and whether you have any special extensions/add-ons installed.
Thank you!